NCT01578109View on ClinicalTrials.gov

Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 13, 2012

Primary Completion Date

October 28, 2020

Study Completion Date

March 7, 2021

Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation
Interventions
PROCEDURE

Bone Marrow Transplantation

Undergo BMT

DRUG

Sorafenib

Given PO

DRUG

Sorafenib Tosylate

Given PO

Trial Locations (2)

21201

University of Maryland/Greenebaum Cancer Center, Baltimore

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01578109 - Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter